Pumpalova, Yoanna S.
Ayeni, Oluwatosin A.
Chen, Wenlong Carl
O’Neil, Daniel S.
Nietz, Sarah
Phakathi, Boitumelo
Buccimazza, Ines
Čačala, Sharon
Stopforth, Laura W.
Farrow, Hayley A.
Joffe, Maureen
Mapanga, Witness
Jacobson, Judith S.
Crew, Katherine D.
Cubasch, Herbert
Ruff, Paul
Neugut, Alfred I.
Funding for this research was provided by:
National Cancer Institute (R01CA192627, R01CA250012, P30 CA13696, K12CA226330, T32 CA094061)
South African Medical Research Council
Article History
Received: 1 March 2021
Accepted: 18 May 2021
First Online: 14 June 2021
Declarations
:
: Dr. Neugut has received consulting fees from Otsuka, United Biosource Corp, Hospira, Eisai, and GlaxoSmithKline, and is on the medical advisory board of EHE Intl. He has also received research funding from Otsuka. Dr. Ruff has received honoraria from Sanofi, Amgen, and Roche and research funding from Amgen, Sanofi, Merck and Novartis. All other authors declare they have no conflicts of interest.
: Approval was obtained from the ethics committees of Columbia University and the University of Witwatersrand. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.